47th week of 2008 patent applcation highlights part 39 |
Patent application number | Title | Published |
20080286244 | Bio-Artificial Materials with Tuneable Properties - This invention relates to methods for preparing biomaterials by applying multiple cycles of tensile loading to compacted collagen gels in order to fuse the collagen fibrils together within the compacted gels. This produces a biomaterial with improved material properties. Biomaterials produced by such methods may be useful, for example, as tissue equivalent implants, in the repair and/or replacement of damaged tissue in an individual. | 2008-11-20 |
20080286245 | PREPARATION OF REGULATORY T CELLS USING ICAM-1 CO-STIMULATION - A method for generating a purified regulatory T cell composition having a CD4 | 2008-11-20 |
20080286246 | Internally administered therapeutic agents for cranial nerve diseases comprising mesenchymal cells as an active ingredient - Intravenous administration of bone marrow cells collected from rat bone marrow or peripheral blood to a rat cerebral infarction model was found to be effective in treating cerebral infarction. Human and murine bone marrow stem cells showed similar effects. Mesenchymal cells such as bone marrow cells, cord blood cells, or peripheral blood cells can be used as agents for in vivo administration against cranial nerve diseases. | 2008-11-20 |
20080286247 | METHOD FOR SELECTIVELY TRANSDUCING PATHOLOGIC MAMMALIAN CELLS USING A TUMOR SUPPRESSOR GENE - A method for transducing a pathologic hyperproliferative mammalian cell is provided by this invention. This method requires contacting the cell with a suitable retroviral vector containing a nucleic acid encoding a gene product having a tumor suppressive function. Also provided by this invention is a method for treating a pathology in a subject caused by the absence of, or the presence of a pathologically mutated tumor suppressor gene. | 2008-11-20 |
20080286248 | Hiv Vif Mutants - A polynucleotide comprising a nucleotide sequence encoding Vif, wherein each of the amino acids corresponding to positions 127, 128, 130, 131, 132 and 142 of the amino acid sequence in FIG. | 2008-11-20 |
20080286249 | USE OF MESENCHYMAL STEM CELLS FOR TREATING GENETIC DISEASES AND DISORDERS - A method of treating a genetic disease or disorder such as, for example, cystic fibrosis, Wilson's disease, amyotrophic lateral sclerosis, or polycystic kidney disease, in an animal comprising administering to said animal mesenchymal stem cells in an amount effective to treat the genetic disease or disorder in the animal. | 2008-11-20 |
20080286250 | Implantable Biocompatible Immunoisolatory Vehicle for Delivery of Gdnf - The present invention relates to devices comprising a composition of human cells secreting a therapeutically effective amount of GDNF (Glial cell-line-derived neurotrophic factor) encapsulated in a device comprising a core and a semipermeable membrane allowing for the diffusion of GDNF protein. The human cells are from one cell line. | 2008-11-20 |
20080286251 | Compositions and Methods for the Enhancement of Chemotherapy with Microbial Cytotoxins - Described herein is a microbial composition used to enhance anti-cancer drugs. Specifically, microbial compositions that comprise a part of or an entire microorganism having surface lectins specific to carbohydrate moieties on tumor surface combined with an oncolytic agent. | 2008-11-20 |
20080286252 | Processing of Natural Polysaccharides by Selected Non-Pathogenic Microorganisms and Methods of Making and Using the Same - The present invention includes compositions and methods of making and using a dietary supplement manufactured from one or more natural polysaccharides previously incubated with a probiotic bacteria in a bioreactor system, wherein the bacteria process the polysaccharides and the resulting processed polysaccharide are provided in the nutritional supplement. | 2008-11-20 |
20080286253 | Composition Comprising Polymeric Material And Uses Thereof - Compositions for the selective delivery of an agent comprising an uncrosslinked starch modified by an acidic group and an agent are described. The compositions are substantially resistant to degradation and thus result in no or substantially no release of the agent in a first environment, and are capable of degradation in a second environment thereby allowing release of the agent. The pKa of the acidic group of the uncrosslinked starch used is higher than the pH of the first environment and lower than or equal to the pH of the subsequent environment. Also described herein are methods of preparing the compositions, methods of using the compositions and the uncrosslinked starch modified by an acidic group, and corresponding commercial packages. | 2008-11-20 |
20080286254 | Composition comprising licorice polyphenol - A composition containing a licorice polyphenol and other active ingredient (antioxidant ingredient, polyphenol other than licorice polyphenol or a component relating to lipid absorption or metabolism) is highly safe, can be produced easily, and can be utilized for foods and drinks such as health food, food with health claims (specified health food, food with nutrient function claims) and the like, pharmaceutical products, quasi-drugs, cosmetics and the like. In addition, since the composition has a body fat accumulation suppressing effect, a body fat decomposition promoting effect or energy production promoting effect, it is useful for the treatment of obesity, metabolic syndrome and the like. | 2008-11-20 |
20080286255 | TREATMENT FOR EYE DISORDER - The present invention relates to altering the physical and/or chemical properties of at least part of at least one tissue in the eye. In a specific embodiment, it relates to the treatment of any eye disorder, although in particular embodiments the individual has a thickened Bruch's membrane. An activating energy source is utilized to effect a controlled diffusion enhancement and/or degradation of Bruch's membrane that enables improved diffusional transport between the choroid and retina. The individual is administered an inactivated diffusion-enhancing molecule that becomes associated with the membrane, which is then precisely exposed to an activating energy source, such as light or ultrasound. | 2008-11-20 |
20080286256 | Methods and Compositions for Killing Spores - The invention provides a sporocidal composition comprising a laccase or a compound exhibiting laccase activity, a source of oxygen and a source of iodide ions. A method of killing or inactivating spores and a method of decontaminating a location, which has been exposed to spores, are also disclosed. | 2008-11-20 |
20080286257 | Compounds for Use in Treating Abnormal Cell Proliferation, and Methods of Producing Same - The invention relates to the modification of recombinant human lysozyme from genetic engineering (rHLys) by reacting with activated polyethylene glycols (PEGs), which are partially binding or saturating with typical linkers one or more out of the six free amino groups of the five lysines (K) present in the rHLys chain. The resulting conjugate compounds of the invention (PEG-rHLys) and their addition salts, inhibit the abnormal cell proliferation and show remarkable antiproliferative and antimetastatic effects. The invention relates also to the use of the new compounds in the preparation of pharmaceutical compositions for treating a disease associated with abnormal cell proliferation, including cancer, by administering said conjugates to a subject in need thereof. | 2008-11-20 |
20080286258 | Bifeprunox mesylate maintenance dose compositions and methods for using the same - The present disclosure provides novel pharmaceutical dosage forms such as a maintenance treatment dose and methods for making the same, and methods for using said compounds and maintenance treatment doses to treat and prevent diseases and/or disorders. | 2008-11-20 |
20080286259 | USE OF ACTIVATED COAGULATION FACTOR VII FOR TREATING THROMBOLYTIC THERAPY-INDUCED MAJOR BLEEDINGS - Major bleedings induced by thrombolytic/fibrinolytic therapy, including intracranial haemorrhages, are treated by administering to a subject suffering from such bleedings an effective amount of activated coagulation factor VII (VIIa) or a functional derivative thereof. | 2008-11-20 |
20080286260 | Diagnostic and Therapeutics for Diseases Associated with Peroxisome Proliferative Activated Receptor Alpha (Ppara) - The invention provides a human PPARA which is associated with the cardiovascular diseases, gastroenterological diseases, cancer, inflammation, hematological diseases, respiratory diseases, neurological diseases and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, gastroenterological diseases, cancer, inflammation, hematological diseases, respiratory diseases, neurological diseases and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of PPARA as well as pharmaceutical compositions comprising such compounds. | 2008-11-20 |
20080286261 | Methods of modulating hair growth - The invention features methods of promoting hair growth in a subject. The methods include inducing or mimicking the effects of Wnt promoted signal transduction, e.g., by increasing the level of Wnt protein or administering an agent which mimics an effect of Wnt promoted signal transduction, e.g., by administering lithium chloride. Methods of inhibiting hair growth are also provided. | 2008-11-20 |
20080286262 | Photosensitizers for Photodynamic Therapy at Infrared Excitation - A photosensitizer that is excitable via infrared radiation and is adapted to be used to treat a selected biological target. The photosensitizer comprises a core nanoparticle adapted to convert infrared radiation into a visible light emission, and a coating disposed about the core nanoparticle. The coating contains a light excitable agent that is adapted to be excited by the visible light emission from the core nanoparticle. The photosensitizer can be surface modified with an antibody to make the photosensitizer specific to the biological target that is to be treated. Such surface modified photosensitizer is introduced to the target site and irradiated with infrared radiation. | 2008-11-20 |
20080286263 | Diagnosis Of Neurodegenerative Diseases - The invention relates to a method of diagnosis of Huntington's Disease in a diagnostic sample of a valid body tissue taken from a human subject, which comprises detecting an altered concentration of a protein in the diagnostic sample, compared with a sample of a control human subject, the protein being selected from: Swiss Prot accession number: Protein name; P10909: Clusterin precursor; P00738: Haptoglobin precursor; P01009: Alpha-1-antitrypsin precursor; P01024: Complement C3 precursor; P01620: 1 g kappa chain V-III region; P01834: 1 g kappa chain C region P01842: 1 g lambda chain C regions; P01857: 1 g gamma-1 chain C region; P01859: Ig gamma-2 chain C region; P01876: 1 g alpha-1 chain C region P02647: Apolipoprotein A-I precursor; P02649: Apolipoprotein E precursor; P02652: Apolipoprotein A-II precursor; P02655: Apolipoprotein C-II precursor; P02656: Apolipoprotein C-II precursor P02671: Fibrinogen alpha/alpha-E chain precursor; P02763: Alpha-1-acid glycoprotein 1 precursor; P02766: Transthyretin precursor; P02768: Serum albumin precursor; P02787: Serotransferrin precursor; P04196: Histidine-rich glycoprotein precursor; P06727: Apolipoprotein A-IV precursor; P19652: Alpha-1-acid glycoprotein 2 precursor; P68871/P02042: Hemoglobin beta chain/Hemoglobin delta chain; P60709: Beta actin. | 2008-11-20 |
20080286264 | Modulation of Muc1 Activity - The invention provides methods of identifying and making compounds that inhibit the interaction between MUC1 and either p53 or TBP. Also embraced by the invention are in vivo and in vitro methods of inhibiting such an interaction and of inhibiting the expression of MUC1 by a cell. | 2008-11-20 |
20080286265 | SUBSTITUTED PHENOXY N-ALKYLATED THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS - The present invention relates to compounds of Formula (I), | 2008-11-20 |
20080286266 | Novel Use of Il-1Beta Compounds - This invention relates to a novel use of IL-1β-ligand/IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1β ligand-IL-1 receptor interaction, IL-1β antibodies or IL-1 receptor antibodies, e.g. IL-1β binding molecules described herein, e.g. antibodies disclosed herein, e.g. IL-1β binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1β ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans. | 2008-11-20 |
20080286267 | Methods for treating nervous system inquiry and disease - The invention is directed to methods for treating nervous system injury and disease, in particular traumatic brain injury and degenerative nervous system disease. Such methods utilize novel compositions, including but not limited to trophic factor-secreting extraembryonic cells (herein referred to as TSE cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), each alone or in combination with each other and/or other agents. | 2008-11-20 |
20080286268 | PROCESSED ECM MATERIALS WITH ENHANCED COMPONENT PROFILES - Described are medical graft materials and devices having improved properties relating to their component profiles. | 2008-11-20 |
20080286269 | Anti-alpha(v)beta(6) antibodies and uses thereof - The present invention is in the fields of cell biology, immunology and oncology. The invention provides humanized antibodies that recognize α | 2008-11-20 |
20080286270 | Stabilized liquid anti-RSV antibody formulations - The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention. | 2008-11-20 |
20080286271 | Methods and Compositions for Modulating Tweak and Fn14 Activity - Agonists and antagonists which modulate the activity of TWEAK and TWEAK receptor are provided. The methods, compositions and kits of the invention may be employed in the treatment of disorders such as cancer and immune-related diseases. | 2008-11-20 |
20080286272 | EphA3 Antibodies for the Treatment of Solid Tumors - The invention provides methods and compositions comprising anti-EphA3 antibodies for the treatment of solid tumors. | 2008-11-20 |
20080286273 | Knowledge-Based Proliferation Signatures and Methods of Use - The present invention provides methods and compositions for predicting patient responses to cancer treatment using a proliferation gene signature. These methods can comprise measuring in a biological sample from a patient the levels of gene expression of a group of the genes designated herein. The present invention also provides for microarrays that can detect expression from a group of genes. | 2008-11-20 |
20080286274 | Vector for Efficient Selection and/or Maturation of an Antibody and Uses Thereof - It is described a vector suitable for efficient selection and/or maturation of a recombinant antibody characterized in that it contains at least one element able to reduce the expression level and/or has an improved efficiency of display of said recombinant antibody. | 2008-11-20 |
20080286275 | Antigen Binding Proteins Directed Against Scavenger Receptor B1 that Inhibit Hcv Replication - The present invention features antigen binding protein that bind to a SR-BI target region identified herein as a region involved in HCV E2 binding. Identified target regions are regions bound by a single-chain antibody of SEQ ID NOs: 1, 2, 3 or 4. | 2008-11-20 |
20080286276 | Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV) - The present invention provides a purified preparation containing, for example, at least one polypeptide selected from the group consisting of proteins encoded by one or more open reading frames (ORF's) of an Iowa strain of porcine reproductive and respiratory syndrome virus (PRRSV), antigenic regions of such proteins which are at least 5 amino acids in length and which effectively protect a porcine host against a subsequent challenge with a PRRSV isolate, and combinations thereof in which amino acids non-essential for antigenicity may be conservatively substituted. The present invention also concerns a vaccine comprising an effective amount of such a protein; antibodies which specifically bind to such a protein; methods of producing the same; and methods of protecting a pig against a PRRSV, treating a pig infected by a PRRSV, and detecting PRRSV in a pig. | 2008-11-20 |
20080286277 | Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof - The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human EGFR. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function. | 2008-11-20 |
20080286278 | Process for in vivo treatment of specific biological targets in bodily fluids - A process for treating biological targets in a fluid of a biological organism, including introducing a fluid comprising a biological target to an assembly comprising an inlet connected to receive the fluid and an outlet connected to pass the fluid from the assembly, wherein the assembly comprises a flow chamber for conveying a flow of the fluid, and a capture zone comprising a target-specific binding agent, wherein during flow of the fluid through the flow chamber, the biological target undergoes flux rolling along the target-specific binding agent. | 2008-11-20 |
20080286279 | Treatment of Severe Community-Acquired Pneumonia by Administration of Tissue Factor Pathway Inhibitor (Tfpi) - Methods for prophylactically or therapeutically treating severe pneumonia involve administration of tissue factor pathway inhibitor (TFPI) or a TFPI analog to patients suffering from or at risk of developing this condition. The methods involve the use of continuous intravenous infusion of TFPI or a TFPI analog, preferably at low doses to avoid adverse side effects. | 2008-11-20 |
20080286280 | Stable Lyophilized Pharmaceutical Preparations of Monoclonal or polyclonal antibodies - The invention concerns lyophilized pharmaceutical preparations of monoclonal or polyclonal antibodies which contain a sugar or an amino sugar, an amino acid and a surfactant as stabilizers. In addition the invention concerns a process for the production of this stable lyophilisate as well as the use of a sugar or amino sugar, an amino acid and a surfactant as stabilizers for therapeutic or diagnostic agents containing antibodies. | 2008-11-20 |
20080286281 | CD25 BINDING MOLECULES FOR THE USE IN THE TREATMENT OF MANIFESTATIONS OF REJECTION IN TRANSPLANTATION - Administration of monoclonal antibodies specific for IL-2R to xenograft recipients, or long-term to immunosuppression-intolerant or non-compliant patients over a period of time beyond the very early phase of organ transplantation, prevents transplant rejection. | 2008-11-20 |
20080286282 | Novel Use of Sulfonamide Compound in Combination with Angiogenesis Inhibitor - The present invention relates to a pharmaceutical composition, a kit and a method for treating cancer and/or a method for inhibiting angiogenesis, comprising a sulfonamide compound in combination with Bevacizumab. | 2008-11-20 |
20080286283 | Treatment of cancer with antibodies to costimulating polypeptide of T cells - A polypeptide (8F4 molecule) with a T-cell costimulating biological activity is disclosed, as well as monoclonal antibodies against the 8F4 molecule and hybridoma cells which produce the monoclonal antibodies, the use as medicaments of substances which inhibit the biological activity of the 8F4 polypeptide, in particular monoclonal antibodies, natural or synthetic ligands, agonists or antagonists, in particular for preventing or treating diseases which involve the immune system, the use of the 8F4 molecule or cells containing the 8F4 molecule as medicaments, in particular for preventing or treating diseases which involve the immune system, and the use of substances which specifically recognize the 8F4 polypeptide, in particular monoclonal antibodies, natural or synthetic ligands, agonists or antagonists, for diagnosing diseases which involve the immune system. | 2008-11-20 |
20080286284 | Compositions of PSMA antibodies - The invention includes antibodies or antigen-binding fragments thereof which bind specifically to conformational epitopes on the extracellular domain of PSMA, compositions containing one or a combination of such antibodies or antigen-binding fragments thereof, hybridoma cell lines that produce the antibodies, and methods of using the antibodies or antigen-binding fragments thereof for cancer diagnosis and treatment. The invention also includes oligomeric forms of PSMA proteins, compositions comprising the multimers, and antibodies that selectively bind to the multimers. | 2008-11-20 |
20080286285 | Methods for Treating Vascular Disease - Compositions and methods included herein describe the treatment of atherosclerosis and other vascular diseases such as thrombosis, restenosis after angioplasty and/or stenting, and vein-graft disease after bypass surgery, by inhibition of the expression or biologic activity of the toll-like receptor 4 (TLR4) and/or myeloid differentiation factor 88 (MyD88). TLR4 cell signal transduction is at least partially responsible for the manifestation, continuation, and/or worsening of atherosclerosis and other forms of vascular disease. The present invention provides several means with which to inhibit this signal transduction pathway by affecting the biological activity of the TLR4 receptor and/or MyD88. | 2008-11-20 |
20080286286 | Methods to Treat Disease States by Influencing the Signaling of Ox-40-Receptors and High Throughput Screening Methods for Identifying Substances Therefor - OX40L inhibits the generation of IL-10-producing Tr1 cells from naïve and memory CD4+ T cells induced by the immunuosuppressive drugs dexamethasone and vitamin D3. This unique function of OX40L is not shared by two other costimulatory TNF-family members, GITR-ligand and 4-1BB-ligand. OX40L also strongly inhibits the generation of IL-10-producing Tr1 cells induced by two physiological stimuli provided by inducible costimulatory ligand and immature DCs and inhibits the production of IL-10 by regulatory T cells. It has thus been shown that signaling the OX40-receptor on human T cells by monoclonal antibodies, small molecules, or OX40L regulates the generation and function of IL-10 producing immunosuppressive T cells. Also provided are high throughput methods for identifying substances that promote or inhibit the generation and function of IL-10 producing T cells. Numerous disease states, such as human allergic, autoimmune, and autoimmune diseases, and cancer, may be treated by targeting OX40/OX40L. | 2008-11-20 |
20080286287 | Methods and Agents for Modulating Cellular Activity - The present invention discloses the use of modified IGFBP-2 and agents that regulate the interaction between HBD of IGFBP-2 and EC or PC matrix components to prevent cellular proliferation invasion and/or migration (metastases). | 2008-11-20 |
20080286288 | Vascular endothelial growth factor 2 - Disclosed are human VEGF-2 antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such antibodies. The present invention relates to methods and compositions for preventing, treating or ameliorating a disease or disorder comprising administering to an animal, preferably a human, an effective amount of one or more VEGF-2 antibodies or fragments or variants thereof. | 2008-11-20 |
20080286289 | Use of B Cell Expansion Agents in Generating Antibodies - A method for efficiently generating antibodies immunizes an animal with a target antigen and a B cell expansion agent, such as an anti-CD40 agonist. The antibodies generated from this method are useful as therapeutic agents, diagnostic agents or research reagents in a variety of diseases and conditions. | 2008-11-20 |
20080286290 | Anti-Cd14 Antibody Fusion Protein - A protein comprising (I) an anti-CD14 antibody or its active fragment, or a derivative thereof and (II) an inhibitor for a protease, or its active fragment, or a derivative thereof is provided. | 2008-11-20 |
20080286291 | Betulinol Derivatives as Anti-Hiv Agents - The present invention relates to methods of treating HIV-1 infection in a subject. These methods involve administering to the subject with HIV-1 infection a therapeutically effective amount of a conjugated or immunoconjugated betulinol derivative compound, or a pharmaceutically acceptable salt or derivative thereof, under conditions effective to treat the subject for HIV-1 infection. Also disclosed are methods inhibiting HIV-1 activity in a cell. These methods involve providing a cell infected with HIV-1 and contacting the cell with a conjugated or immunoconjugated betulinol derivative compound, or a pharmaceutically acceptable salt or derivative thereof, under conditions effective to inhibit HIV-1 activity in the cell. | 2008-11-20 |
20080286292 | MOLECULAR VACCINE LINKING INTERCELLULAR SPREADING PROTEIN TO AN ANTIGEN - Superior molecular vaccines comprise nucleic acids, including naked DNA and replicon RNA, that encode a fusion polypeptide that includes an antigenic peptide or polypeptide against which an immune response is desired. Fused to the antigenic peptide is an intercellular spreading protein, in particular a herpes virus protein VP22 or a homologue or functional derivative thereof. Preferred spreading proteins are VP22 from HSV-1 and Marek's disease virus. The nucleic acid can encode any antigenic epitope of interest, preferably an epitope that is processed and presented by MHC class I proteins. Antigens of pathogenic organisms and cells such as tumor cells are preferred. Vaccines comprising HPV-16 E7 oncoprotein are exemplified. Also disclosed are methods of using the vaccines to induce heightened T cell mediated immunity, in particular by cytotoxic T lymphocytes, leading to protection from or treatment of a tumor. | 2008-11-20 |
20080286293 | PROMISCUOUS PAP CD4 T CELL EPITOPES - The present invention relates to the discovery of novel T cell epitopes of the human prostatic acid phosphatase (PAP) protein that is promiscuous for at least 15 different HLA-DR alleles. The invention also relates to compositions that contain one of the novel epitopes or a fusion peptide of such an epitope and a heterologous polypeptide. Further disclosed herein is the use of the epitopes or their fusion peptides, and compositions containing the epitopes or their fusion peptides. | 2008-11-20 |
20080286294 | Nodavirus-Vlp Immunization Composition - The present invention relates to an immunogenic composition for fish comprising nodavirus virus-like particles (VLPs) formed with nodavirus capsid protein assembly, for use as a vaccine. This composition is suitable for administration to fish via the intramuscular or intraperitoneal route, or by bath and/or via the oral route. The invention also relates to the use of such VPLs for the manufacturing of a vaccine for treating or preventing fish against a nodavirus infection. Fish farming baths and concentrates comprising the nodavirus VLP composition, as well as fish farming methods, are also encompassed in the present invention. | 2008-11-20 |
20080286295 | USE OF RECOMBINANT ANTIGENS TO DETERMINE THE IMMUNE STATUS OF AN ANIMAL - The present invention includes a method to determine the immune status of an animal that includes the steps of (a) contacting a biological specimen of the animal with a recombinant infectious agent antigen that is specific for detecting an antibody selective for that infectious agent, under conditions suitable for formation of a complex between the recombinant antigen and the antibody and (b) detecting the presence or absence of the complex, wherein presence or absence of a complex is indicative of the immune status of the animal. Preferably such a method indicates whether the animal should be vaccinated. The present invention also includes an assay comprising (a) a recombinant infectious agent antigen that is specific for detecting an antibody selective for that infectious agent; and (b) a means to detect an antibody that selectively binds to the recombinant antigen. Also included in the present invention are recombinant antigens and nucleic acid molecules encoding such antigens as well as methods to produce and use such nucleic acid molecule and recombinant antigens. | 2008-11-20 |
20080286296 | Cyclic-Dinucleotides and Its Conjugates as Adjuvants and Their Uses in Pharmaceutical Compositions - The present invention relates to new adjuvants and the uses in pharmaceutical compositions, like in vaccines. In particular, the present invention provides new compounds useful as adjuvants and/or immunomodulators for prophylactic and/or therapeutic vaccination in the treatment of infectious diseases, inflammatory diseases, autoimmune diseases, tumors, allergies as well as for the control of fertility in human or animal populations. The compounds are particularly useful not only as systemic, but preferably as mucosal adjuvants. In addition, the invention relates to its uses as active ingredients in pharmaceutical compositions. | 2008-11-20 |
20080286297 | Chimeric Carrier Molecules for the Production of Mucosal Vaccines - The invention relates to a protein complex for the delivery of an antigen to and across mucosal surfaces and the production of said complex in a host cell, such as a plant. Provided is a protein complex comprising at least two, preferably identical, subunits wherein at least one subunit is unaltered and at least one subunit is fused to a first molecule of interest and wherein the protein complex is able to interact with a cell surface receptor via said subunits. Also provided is a method for producing a protein complex according to the invention, comprising a) providing a host cell with a nucleotide sequence encoding an unaltered subunit and a nucleotide sequence encoding a molecule of interest, wherein at least one molecule of interest is fused to a subunit; b) culturing said host cell thereby allowing expression of said nucleotide sequences and allowing for assembly of the protein complex; c) isolating the complex; d) determining the binding of the complex to a cell surface receptor or to a molecule which mimics a cell surface receptor | 2008-11-20 |
20080286298 | Compositions Comprising Hypsizygus Ulmarius Extract - Disclosed are topical compositions comprising extracts of | 2008-11-20 |
20080286299 | FILM-FORMING RESINS AS A CARRIER FOR TOPICAL APPLICATION OF PHARMACOLOGICALLY ACTIVE AGENTS - The invention provides a biological dressing for treatment of a dermatological disease comprised of one or more resins or other film-forming agents, a topically acceptable volatile solvent, and a pharmacologically active agent. The combined one or more resins are present in a suitable amount such that the composition, when the solvent evaporates, will dry to form a solid coating that sticks to the skin, nail or mucosal membrane to which the composition is applied, and maintain the pharmacologically active agent over a sustained period of time in contact with sites on the skin or mucosal membranes exhibiting symptoms of the disease. Methods are provided for treating symptoms of dermatological diseases with such a pharmacological composition. | 2008-11-20 |
20080286300 | Analysis of Saccharide Vaccines Without Interference - The invention is based on methods that allow analysis of mixed meningococcal saccharides from multiple serogroups even though they share monosaccharide units. With a combination of saccharides from serogroups C, W135 and Y, the invention analyses sialic acid, glucose and galactose content. The glucose and galactose results are used to directly quantify saccharides from serogroups Y and W135, respectively, and the combined glucose and galactose content is subtracted from the sialic acid content to quantify saccharides from serogroup C. The three serogroups can thus be resolved even though their monosaccharide contents overlap. The three different monosaccharide analyses can be performed on the same material, without interference between the monosaccharides and without interference from any other saccharide materials in the composition (e.g. lyophilisation stabilisers). The method can be used to analyse total and free saccharide in conjugate vaccines and simplifies quality control of vaccines containing capsular saccharides from multiple serogroups. | 2008-11-20 |
20080286301 | Treatment of diabetes - Insulin-requiring diabetes in a mammal can be treated by a process comprising administering to the mammal in a suitable regimen an effective amount of insulin and an effective amount of a peptide comprising a peptide selected from the group consisting of
| 2008-11-20 |
20080286302 | Safe Mutant Viral Vaccines - The present invention provides safe vaccines and methods of preparing such vaccines. The vaccines of the present invention contain at least two live mutant viruses of the same family or nucleic acid molecules encoding such viruses, wherein each of the two viruses or the encoding nucleic acids contains a mutation that confers a desirable phenotype and the mutations in the viruses reside in the same genomic site such that the mutant viruses cannot recombine with each other to eliminate the mutations. | 2008-11-20 |
20080286303 | Multi-component vaccine comprising at least two antigens from haemophilus influenzae to protect against disease - A multi-component immunogenic composition confers protection on an immunized host against infection caused by | 2008-11-20 |
20080286304 | Modifying Leukocyte Function - Use of PREPS and/or L-particles for the manufacture of a medicament for modifying or regulating leukocyte function. | 2008-11-20 |
20080286305 | Antigen Transduced T Cells Used as a Delivery System for Antigens - A delivery system comprising a T cell comprising at least one antigen capable of loading antigen-presenting-cells with the antigen. | 2008-11-20 |
20080286306 | HIV vaccines based on Env of multiple clades of HIV - In one embodiment, the invention provides a multiclade HIV plasmid DNA or viral vector vaccine including components from different clades of Env (optionally Env chimeras) and Gag-Pol-(optionally)Nef from a single clade. The vaccine of the invention may further include V1, V2, V3, or V4 deletions or combinations thereof. In another embodiment, the invention provides multiclade HIV envelope immunogens. | 2008-11-20 |
20080286307 | Two-Step Temperature Profile for the Propagation of Viruses - The present invention provides a method for the production of a virus. The method includes providing a host cell that has been infected by the virus and cultivating the infected host cell at two different temperatures. The virus produced by the cultivation steps is subsequently collected. By using the dual temperature cultivation process, high titer and improved purity can be obtained. | 2008-11-20 |
20080286308 | Pathogenic Bovine Enterovirus, Vaccines, and Diagnostic Methods - The isolation of a novel pathogenic bovine enterovirus is described. The novel pathogenic bovine enterovirus is used to develop antibodies and immunogenic compositions against the novel pathogenic bovine enterovirus. Diagnostic assays are described. | 2008-11-20 |
20080286309 | Process for Preparing Variant of Erysipelothrix Rhusiopathiae Surface Protective Antigen in E. Coli - A variant of | 2008-11-20 |
20080286310 | Live Attenuated Bacterial Vaccine to Reduce or Inhibit Carriage and Shedding of Enterohemorrhagic Escherichia Coli in Cattle - The invention provides live, attenuated enterohemorrhagic | 2008-11-20 |
20080286311 | Protein Allergen Derivatives - The present invention relates to a method for producing derivatives of wild-type protein allergens with reduced allergenic activity, characterized in by the following steps: providing a wild-type protein allergen with an allergenic activity, splicing said wild-type protein allergen into two parts, said two parts having a reduced allergenic activity or lacking allergenic activity and rejoining said two fragments in inverse orientation; as well as allergen derivatives. | 2008-11-20 |
20080286312 | Membrane-anchored beta2 microglobulincovalently linked to MHC class I peptide epitopes - The invention provides a polynucleotide comprising a sequence encoding a polypeptide that is capable of high level presentation of antigenic peptides on antigen-presenting cells, wherein the polypeptide comprises a β2-microglobulin molecule that is linked through its carboxyl terminal to a bridge peptide which spans the whole distance to the cell membrane, said bridge peptide being linked to a polypeptide stretch consisting of the full or partial transmembrane and/or cytoplasmic domains selected from the group consisting of a toll-like receptor (TLR) polypeptide, a CD40 polypeptide, and TLR and CD40 polypeptides fused in tandem, that allows the anchorage of the β2-microglobulin molecule to the cell membrane, and through its amino terminal to at least one antigenic peptide comprising an MHC class I epitope, wherein said antigenic peptide is preferably derived from a tumor-associated antigen or from a pathogenic antigen. Antigen presenting cells and DNA and cellular vaccines for treatment of cancer and infectious diseases, are also provided. | 2008-11-20 |
20080286313 | Peptide Vaccines for the Treatment of Cancers - The present invention provides a method for treating a cancer patient which comprises administering a therapeutically effective amount of a cancer antigen peptide to the patient in need thereof, wherein the method comprises the steps of
| 2008-11-20 |
20080286314 | Dendritic cells loaded with heat shocked melanoma cell bodies - The present invention includes compositions and methods for the isolation, purification and preparation of immunogenic antigens for the production of customized cancer vaccines that include dendritic cells that are contacted with an antigen that includes heat-shocked cancer cells. | 2008-11-20 |
20080286315 | Methionine Enkephalin as an Adjuvant for Vaccine Immunizations - The present invention provides a method of stimulating dendritic cells, comprising contacting the dendritic cells with methionine enkephalin. The present invention also provides methods of enhancing an immune response to an antigen in a mammal. In a first method, dendritic cells are isolated from the mammal. The dendritic cells are then contacted with methionine enkephalin for a time sufficient to stimulate the cells. Next, the stimulated dendritic cells are contacted with the antigen of interest for a time sufficient for the cells to process the antigen. The dendritic cells are then injected into the mammal. The dendritic cells may be injected into the animal either on their own, or along with methionine enkephalin and/or the antigen. In a second method, the antigen of interest and methionine enkephalin are administered to the mammal. The present invention also provides compositions for administration to a mammalian subject having a tumor. | 2008-11-20 |
20080286316 | Lipid raft, caveolin protein, and caveolar function modulation compounds and associated synthetic and therapeutic methods - The present invention is directed to the modulation of lipid rafts, caveolin proteins, or caveolar functions and processes by platinum(IV) compounds. Caveolae and/or lipid rafts are associated with cell transcription regulation, membrane and cellular transport, cell membrane receptor function, cellular trafficking, antigen presentation, cell differentiation and activation, cytokine modulation, membrane structure and function, and protein modulation. Caveolae, caveolin proteins and lipid rafts are known therapeutic targets for numerous biological functions. Diseases and disorders currently known to be therapeutically targeted through caveolae and/or lipid rafts include diabetes, cancer, cardiovascular diseases, atherosclerosis, pulmonary fibrosis, multiple sclerosis, viral and prion diseases, neuronal disorders, degenerative muscular dystrophies, and autoimmune disorders. | 2008-11-20 |
20080286317 | Self-Adhesive Film for Teeth - Monolayered or multilayered, film-shaped, pressure-sensitive adhesive preparations for application in the oral region and a process for manufacturing such preparations. The preparations contain at least one polymethyl vinyl ether-maleic acid anhydride copolymer, polyvinyl acetate and/or at least one copolymer of the polyvinyl acetate with vinyl alcohol esters of fatty acids, as well as at least one cosmetic and/or pharmaceutical active substance. | 2008-11-20 |
20080286318 | Oral Care Compositions - An oral care composition containing polymeric microparticles highly loaded with an oral care compound is disclosed. | 2008-11-20 |
20080286319 | Antimicrobial surfaces and methods for preparing antimicrobial surfaces - The present invention relates to biocidal articles. In an embodiment the biocidal article comprises a plurality of polymers having biocidally active groups. The polymers are attached to a surface and may have a polydispersity less than 3. The biocidally active groups may comprise at least one of a quaternary ammonium salt, a quaternary phosphonium salt or a chloroamine. The attached polymers may be any microstructure, topology or composition, such as, a homopolymer, block copolymer, multiblock copolymer, a random copolymer, graft polymer, a branched or a hyperbranched polymer, and a gradient copolymer. The present invention also comprises a process for the preparation of a biocidal article. Embodiments of the process comprise polymerizing radically polymerizable monomers from an initiator attached to a surface, wherein at least a portion of the monomers comprise a group capable of being converted to a biocidally active group, and converting the group to the biocidally active group. | 2008-11-20 |
20080286320 | Absorbent article comprising a lotion composition for reducing adherence of feces or menses to the skin - The present invention relates to lotion compositions comprised on a body facing surface of an absorbent article such as a diaper, training pants or adult incontinence product. The lotion composition may be used for reducing the adherence of feces or menses to the human skin. The lotion composition comprises at least two compounds wherein one first compound is liquid at 25° C. and at least one second component which is solid at 25° C. An effective amount of the lotion composition is comprised on a body facing surface of an absorbent article which is intended to be worn by a wearer. | 2008-11-20 |
20080286321 | Polymer No Donor Predrug Nanofiber Coating for Medical Devices and Therapy - The present invention relates to nanofibers that produce therapeutic amounts of nitric oxide after a delay period, which allows time to install or implant the device into a patient. The nitric oxide release is thus localized to the area of the organism where NO dosing is indicated. The delay time is achieved by cospinning the NO-producing fiber with a fiber that tends to sequester the former's NO-producing functional groups. Fibers of the present invention may be incorporated into medical devices such as stents or other implantable medical devices to prevent the formation of adhesions or scarring in the area of the implant. | 2008-11-20 |
20080286322 | METHODS AND DEVICES FOR THE SUSTAINED RELEASE OF MULTIPLE DRUGS - The invention relates to an drug delivery device and a method for delivering multiple drugs over a prolonged period of time. The drug delivery device has two or more unitary segments comprising a drug-permeable polymeric substance, wherein at least one of the segments further comprises a pharmaceutically active agent. The invention also relates to a method for the treatment of a benign ovarian secretory disorder in a female mammal, a method of contraception, and a method of relieving the symptoms associated with menopausal, perimenopausal and post-menopausal periods in a woman. | 2008-11-20 |
20080286323 | Human Therapeutic Cells Secreting Nerve Growth Factor - The present invention relates to human cell lines genetically modified to overexpress bioactive NGF. In another aspect the present invention relates to encapsulated human cell lines genetically modified to overexpress bioactive NGF, which can be used in therapy of Alzheimer's disease, peripheral neuropathy and other neurological disorders amenable to local and prolonged NGF therapy. | 2008-11-20 |
20080286324 | MEDIA AND DEVICES FOR COLD STORAGE OF THERAPEUTIC CELLS - The invention provides a composition for cold storage of cells which includes a population of isolated stem cells, a cell medium, and isolated trophic factors, as well as devices having a plurality of the trophic factors. | 2008-11-20 |
20080286325 | CYCLODEXTRIN ELUTION MEDIA FOR MEDICAL DEVICE COATINGS COMPRISING A TAXANE THERAPEUTIC AGENT - The present disclosure provides methods of measuring the release of a taxane therapeutic agent from a medical device as a function time in contact with a suitable elution medium. The method preferably comprises the step of contacting a coated medical device comprising a taxane therapeutic agent with an elution medium comprising a cyclodextrin to provide an elution profile indicative of the composition or configuration of a medical device coating comprising a taxane therapeutic agent. The elution profile can provide information about the medical device coating that is useful in lot release testing. | 2008-11-20 |
20080286326 | Medical devices having antifouling character - According to an aspect of the invention, medical devices are provided which include (a) a substrate and (b) a coating that includes an antifouling copolymer, an adhesive copolymer, or both. Antifouling copolymers for use in conjunction with the present invention contain (i) at least one antifouling polymer block having multiple pendant alkoxy functional groups along the polymer backbone and (ii) at least one additional polymer block. Adhesive copolymers for use in conjunction with the present invention contain (i) at least one adhesive polymer block having multiple pendant ring-hydroxyl-substituted aromatic groups along the polymer backbone and (ii) at least one additional polymer block. | 2008-11-20 |
20080286327 | THOMBOLYSIS AND CHRONIC ANTICOAGULATION THERAPY - Method and systems of treating a patient with at least one of a myocardial infarction, a stroke, and a pulmonary embolism include providing a stimulator coupled to at least one electrode and a catheter, configuring one or more stimulation parameters to treat at least one of a myocardial infarction, a stroke, and a pulmonary embolism, programming the stimulator with the one or more stimulation parameters, delivering with the stimulator via the catheter at least one drug to at least one tissue in accordance with the one or more stimulation parameters, and limiting perfusion of the at least one tissue by delivering electrical stimulation with the stimulator via the at least one electrode to the at least one tissue. | 2008-11-20 |
20080286328 | Implant and Production Method for Said Implant - The invention relates to an implant, e.g. a stent, bone replacement material, a prosthesis, a scaffold or similar, which comprises a coating at least in those surface areas that come into contact with hard and/or soft tissue when implanted. To ensure that the active ingredient contained in the coating (bisphosphonate) is released into the surrounding tissue or can act in the latter in a controlled manner at the correct speed, the coating is characterised in that it contains bisphosphonate, the respective pharmaceutically compatible salts or esters of the latter, in addition to at least one amphiphilic component, selected from the group containing branched or linear, substituted or unsubstituted, saturated or partially unsaturated C10-C30 alkyl-, alkenyl, alkylaryl-, aryl-, cycloalkyl-, alkylcycloalkyl-, alkylcycloaryl-carboxylates, -phosphates or -sulfates or mixtures thereof and/or a water-soluble ionic polymer component. The invention also relates to a method for producing an implant of this type and to a specific composition, which can be used to produce a coating of this type. | 2008-11-20 |
20080286329 | Methods and Apparatus for Manufacturing Plasma Based Plastics and Bioplastics Produced Therefrom - Blood-derived plastic articles prepared from compositions including blood and, in some embodiments, at least one crosslinking agent and/or at least one biological response modifier, that can be useful for biological applications such as wound repair and tissue grafts; methods of making and using the same; methods for assessing the concentration of a biological response modifier in an article; and systems for preparing blood-derived plastic articles are provided. | 2008-11-20 |
20080286330 | METHODS AND DEVICE TO NEUTRALIZE SOLUBLE TOXIC AGENTS IN THE BRAIN - Methods, agents and devices for treating a patient to reduce accumulation of certain proteins in the brain are described. Such proteins include Aβ, and the methods, agents and devices are useful for reducing the accumulation of Aβ, which is a principal constituent of the plaques associated with such diseases as Alzheimer's disease (AD). Antibodies to Aβ, when delivered systemically or directly into the central nervous system, improve cognitive deficits in a transgenic mouse model of AD. However, unlike peripheral of antibodies to Aβ, which increased cerebral vascular plaques and hemorrhages, direct central administration did not result in such an increase cerebral vascular plaques and hemorrhages. | 2008-11-20 |
20080286331 | COMPOSITION FOR AN INJECTABLE BONE MINERAL SUBSTITUTE MATERIAL - The invention refers to an injectable composition for a bone mineral substitute material, which comprises a dry powder mixed with an aqueous liquid. The powder comprises a first reaction component comprising a calcium sulphate hemihydrate with the capability of being hardened to calcium sulphate dihydrate when reacting with said aqueous liquid; a second reaction component, which comprises a calcium phosphate with the capability of being hardened to a calcium phosphate cement when reacting with said aqueous liquid; and at least one accelerator for the reaction of said first and/or second reaction component with said aqueous liquid. A method of producing an injectable bone mineral substitute material is also provided, wherein the composition is mixed in a closed mixing and delivery system for delivery. | 2008-11-20 |
20080286332 | Implantable medical devices with a topcoat layer of phosphoryl choline acrylate polymer for reduced thrombosis, and improved mechanical properties - The present invention relates to implantable medical devices coated with phosphoryl choline acrylate polymer topcoat layer, an acrylate copolymer layer containing a therapeutic agent, and their use in the treatment of vascular diseases. | 2008-11-20 |
20080286333 | Medical devices having coating with improved adhesion - According to an aspect of the present invention, a medical device is provided which comprises a metallic substrate and polymeric region disposed over and in contact with the metallic substrate. The polymeric region comprises (a) a block copolymer that comprises (i) a hard polymer block that comprises a high Tg monomer and (ii) a soft polymer block that comprises a low Tg monomer, (b) an adhesion promoting copolymer that comprises (i) a first monomer that covalently or non-covalently bonds with the metallic substrate and (ii) a second monomer that is compatible with the low Tg monomer and/or the high Tg monomer and (c) a therapeutic agent. The polymeric region may further comprise an optional polymer that is used to tailor the release rate of the therapeutic agent. | 2008-11-20 |
20080286334 | OCULAR IMPLANT MADE BY A DOUBLE EXTRUSION PROCESS - The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release. | 2008-11-20 |
20080286335 | Enhancement Of The Calcium Sensing Receptor - The disclosure relates to medical devices capable of enhancing ossification in a subject. More specifically, the disclosure relates to the use of devices comprising a releasable calcium sensing receptor agonist and a releasable calcium salt. | 2008-11-20 |
20080286336 | OCULAR IMPLANT MADE BY A DOUBLE EXTRUSION PROCESS - The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release. | 2008-11-20 |
20080286337 | Method of treating a disease in an eye using a scleral lens - A scleral lens is provided with a drug that is retained in the reservoir of fluid between the scleral lens and the cornea. This system can be used to deliver drugs not currently used because of poor bioavailability, to increase bioavailability of drugs used in patients already wearing a scleral lens, and to improve bioavailability in patients who are not currently wearing the lens. Dosing can be provided less frequently, thus decreasing the risk of non-compliance. | 2008-11-20 |
20080286338 | Drug delivery system with scleral lens - A scleral lens is provided with a drug that is retained in the reservoir of fluid between the scleral lens and the cornea. This system can be used to deliver drugs not currently used because of poor bioavailability, to increase bioavailability of drugs used in patients already wearing a scleral lens, and to improve bioavailability in patients who are not currently wearing the lens. Dosing can be provided less frequently, thus decreasing the risk of non-compliance. | 2008-11-20 |
20080286339 | METHODS AND DEVICES FOR THE SUSTAINED RELEASE OF MULTIPLE DRUGS - The invention relates to an drug delivery device and a method for delivering multiple drugs over a prolonged period of time. The drug delivery device has two or more unitary segments comprising a drug-permeable polymeric substance, wherein at least one of the segments further comprises a pharmaceutically active agent. The invention also relates to a method for the treatment of a benign ovarian secretory disorder in a female mammal, a method of contraception, and a method of relieving the symptoms associated with menopausal, perimenopausal and post-menopausal periods in a woman. | 2008-11-20 |
20080286340 | Buffered nicotine containing products - A pharmaceutical oral formulation for delivering nicotine in any form to a subject by transmucosal uptake in the oral cavity comprising nicotine in any form, wherein said oral formulation is buffered with at least one amino acid, preferably at least one endogenous amino acid. Also contemplated is a method for the oral delivery of nicotine in any form, a method for the reduction of the urge to smoke or use tobacco as well as methods for manufacturing the oral formulation, the use of said oral formulation for obtaining transmucosal uptake of nicotine in the oral cavity of a subject, and use of nicotine for the production of an oral formulation as per above for the treatment of a disease selected from the group consisting of tobacco or nicotine dependence, Alzheimer's disease, Crohn's disease, Parkinson's disease, Tourette's syndrome, ulcerous colitis and post-smoking-cessation weight control. | 2008-11-20 |
20080286341 | Buffered coated nicotine containing products - Coated oral dosage forms for the delivery of nicotine in any form to a subject by rapid intraoral delivery of nicotine comprising at least one core, nicotine in any form and/or a nicotine mimicking agent, at least one coating layer and optionally at least one or more other additives, wherein said at last one coating layer is buffered, whereby is used at least one amino acid as buffering agent. Also contemplated are a method for the delivery of nicotine in any form, a method for the reduction of the urge to smoke or use tobacco as well as a method for producing said coated product and use of the same for obtaining a rapid intraoral uptake of nicotine. | 2008-11-20 |
20080286342 | Form of Administration Based on Crosslinked Hydrophilic Polymers - The invention relates to a film-shaped form of administration for topically administering at least one agent and/or nutrient to a living being. Said form of administration comprises at least one agent-containing and/or nutrient-containing layer that is based on crosslinked hydrophilic polymers which are crosslinked with at least one polyacrylic acid derivative. | 2008-11-20 |
20080286343 | Solid form - A solid form comprising at least one film enrobing a compacted fill material having at least one active material contained in a matrix and having low friability, a density of at least 0.5 g/ml based on the total solid volume of the solid form and a tensile strength less than 0.9 MPa and which exhibits a controlled release profile for release of the active material. Zero order release may be achieved. | 2008-11-20 |